{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:03:13Z","timestamp":1792807393507,"version":"4.5.0"},"reference-count":62,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2017,5,4]]},"DOI":"10.1080\/14787210.2017.1308251","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T12:55:07Z","timestamp":1489755307000},"page":"425-433","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":86,"title":["The antibiotic pipeline: reviving research and development and speeding drugs to market"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-6978","authenticated-orcid":false,"given":"Katherine H.","family":"Luepke","sequence":"first","affiliation":[{"name":"Medical Affairs Strategic Solutions, LLC, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John F.","family":"Mohr","sequence":"additional","affiliation":[{"name":"Medical Affairs Strategic Solutions, LLC, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"key":"CIT0001","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2013 [May 26, 2016]. Available from: http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/."},{"key":"CIT0002","unstructured":"McNeill RND, Abutaleb Y. Reuters Investigates: The Uncounted: The deadly epidemic America is ignoring. October 31, 2016. Available from: http:\/\/www.reuters.com\/investigates\/special-report\/usa-uncounted-surveillance\/#sidebar-abrcdc-space."},{"key":"CIT0003","unstructured":"Review on Antimicrobial Resistance. Securing New Drugs for Future Generations: The Pipeline of Antibiotics 2015 May 26, 2016. Available from: http:\/\/amr-review.org\/sites\/default\/files\/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf."},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01277-13"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1038\/472032a"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1868"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1186\/cc13948"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2014.0086"},{"key":"CIT0009","unstructured":"The Pew Charitable Trusts: A Scientific Roadmap for Antibiotic Discovery 2016 January 26, 2017. Available from: http:\/\/www.pewtrusts.org\/en\/research-and-analysis\/reports\/2016\/05\/a-scientific-roadmap-for-antibiotic-discovery."},{"key":"CIT0010","volume-title":"Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies: Workshop Summary","author":"Institute of Medicine (IOM)","year":"2010"},{"key":"CIT0011","unstructured":"The Pew Charitable Trusts: The Critical Need for New Antibiotics January 26, 2017. Available from: http:\/\/www.pewtrusts.org\/en\/multimedia\/data-visualizations\/2016\/the-critical-need-for-new-antibiotics."},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-0691.2004.1006.x"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2003.08.003"},{"key":"CIT0014","unstructured":"Sertkaya AEJ, Birkenbach A, Franz C, et al. Analytical Framework for Examining the Value of Antibacterial Products. Lexington, MA: Eastern Research Group;2014 April 15. HHSP23337004T."},{"key":"CIT0015","unstructured":"Dollar Times Inflation Calculator [May 26, 2016]. Available from: http:\/\/www.dollartimes.com\/calculators\/inflation.htm."},{"issue":"2","key":"CIT0016","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1093\/cid\/ciw258","volume":"63","author":"Knirsch C","year":"2016","journal-title":"Clin Infect Dis"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw314"},{"key":"CIT0018","volume-title":"Cost Drivers of a Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP\/VABP) Phase Three Clinical Trials","author":"Stergiopoulos STP","year":"2015"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1086\/653033"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1086\/653064"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.12480"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw244"},{"key":"CIT0023","unstructured":"Achaogen, Inc. Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin 2016 [cited 2017 January 27, 2017]. Available from: http:\/\/investors.achaogen.com\/releasedetail.cfm?ReleaseID=1003671."},{"key":"CIT0024","unstructured":"Shionogi I. Shionogi Announces Positive Top-Line Results for Cefiderocol Pivotal cUTI Clinical Trial 2017 [January 27, 2017]. Available from: http:\/\/www.shionogi.com\/newsroom\/article.html#122507."},{"key":"CIT0025","unstructured":"Merck Sharp & Dohme Corp. Efficacy and Safety of Imipenem+Cilastatin\/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) (RESTORE-IMI 1) 2016 [cited 2017 January 27, 2017]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show?term=relebactam&rank=1."},{"key":"CIT0026","unstructured":"Merck Sharp & Dohme Corp. Imipenem\/Relebactam\/Cilastatin Versus Piperacillin\/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (RESTORE-IMI 2) 2016 [cited 2017 January 27, 2017]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02493764?term=relebactam&rank=2."},{"key":"CIT0027","unstructured":"The Medicines Company. FDA Grants Fast Track Status for Investigational Antibiotic CARBAVANCE\u00ae (meropenem-vaborbactam) 2016 [January 27, 2017]. Available from: http:\/\/www.themedicinescompany.com\/investors\/news\/fda-grants-fast-track-status-investigational-antibiotic-carbavance%C2%AE-meropenem."},{"key":"CIT0028","unstructured":"Innovative Medicines Initiative: New Drugs for Bad Bugs [cited 2016 May 26]. Available from: http:\/\/www.imi.europa.eu\/content\/nd4bb."},{"key":"CIT0029","unstructured":"Review on Antimicrobial Resistance: Tackling Drug-Resistant Infections Globally: Final Report and Recommendations 2016 May 19, 2016. Available from: http:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf."},{"key":"CIT0030","unstructured":"National Action Plan for Combating Antibiotic-Resistant Bacteria. Washington: White House. DC2015. https:\/\/obamawhitehouse.archives.gov\/sites\/default\/files\/docs\/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf"},{"key":"CIT0031","volume-title":"Global Action Plan on Antimicrobial Resistance","year":"2015"},{"key":"CIT0032","volume-title":"NIAID\u2019s Antibacterial Resistance Program: Current Status and Future Directions","year":"2014"},{"key":"CIT0033","unstructured":"The Pew Charitable Trusts. New Federal Funds Support Targeted Research on Toughest Superbugs 2017 [cited 2017 January 27, 2017]. Available from: http:\/\/www.pewtrusts.org\/en\/research-and-analysis\/analysis\/2017\/01\/09\/new-federal-funds-support-targeted-research-on-toughest-superbugs."},{"key":"CIT0034","unstructured":"US Department of Health and Human Services. Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antimicrobial-Resistant Gram-Negative Bacteria (R01) 2016 [cited 2017 January 27, 2017]. Available from: https:\/\/grants.nih.gov\/grants\/guide\/rfa-files\/RFA-AI-16-081.html."},{"key":"CIT0035","unstructured":"Antibacterial Resistance Leadership Group [May 26, 2016]. Available from: http:\/\/www.arlg.org\/."},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1089\/hs.2014.0081"},{"key":"CIT0037","unstructured":"CARB-X: Xccelerating global antibacterial innovation. [November 8, 2016]. Available from: www.carb-x.org."},{"key":"CIT0038","unstructured":"Innovative Medicines Initiative New Drugs for Bad Bugs. The Innovative Medicines Initiative response to antimicrobial resistance2016 [May 2016]; 2017. Available from: http:\/\/www.imi.europa.eu\/sites\/default\/files\/uploads\/documents\/Publications\/IMIandAMR_factsheet_vMay2016.pdf."},{"key":"CIT0039","unstructured":"Clinical Trials Transformation Initiative: Antibacterial Drug Development (ABDD) 2017 [cited 2017 January 27, 2017]. Available from: https:\/\/www.ctti-clinicaltrials.org\/programs\/antibacterial-drug-development."},{"key":"CIT0040","unstructured":"E K. Taking the mystery out of expedited approvals2015 2017 [cited January 27, 2017]. Available from: http:\/\/weinberggroup.com\/fda-expedited-approvals\/."},{"key":"CIT0041","unstructured":"Somerville SHKJ FDA\u2019s Expedited Review Process: The Need for Speed. Applied Clinical Trials [Internet]. 2015 January 27, 2017. Available from: http:\/\/www.appliedclinicaltrialsonline.com\/fda-s-expedited-review-process-need-speed."},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1177\/0098858816658275"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0291"},{"key":"CIT0044","unstructured":"US Food and Drug Administration. CDER Breakthrough Therapy Designation Approvals 2016 [cited 2017 January 27, 2017]. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/DrugandBiologicApprovalReports\/NDAandBLAApprovalReports\/UCM481542.pdf."},{"key":"CIT0045","unstructured":"US Food and Drug Administration. CDER Drug and Biologic Accelerated and Restricted Distribution Approvals 2017 [cited January 27, 2017]. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/DrugandBiologicApprovalReports\/NDAandBLAApprovalReports\/UCM404466.pdf."},{"key":"CIT0046","volume-title":"Generating Antibiotic Incentives Now (GAIN) Act"},{"key":"CIT0047","unstructured":"21st Century Cures Act. Sect. 3042 (2016)."},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70293-1"},{"key":"CIT0049","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Antibacterial Therapies for Patients with Unmet Medical Need for the Treatment of Serious Bacterial Diseases (Draft Guidance). 2013. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM359184.pdf"},{"key":"CIT0050","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products","author":"European Medicines Agency","year":"2016"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.007"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.9658"},{"key":"CIT0053","doi-asserted-by":"crossref","unstructured":"Mendoza RL. The 21st Century Cures Act: pharmacoeconomic boon or bane? J Med Econ. 2017 Apr;20(4):315-317.","DOI":"10.1080\/13696998.2017.1282865"},{"key":"CIT0054","doi-asserted-by":"crossref","unstructured":"Holland TL, Mikita S, Bloom D, et al. Patient and physician attitudes regarding risk and benefit in streamlined development programmes for antibacterial drugs: a qualitative analysis. BMJ Open. 2016 Nov 10;6(11):e013561.","DOI":"10.1136\/bmjopen-2016-013561"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70780-7"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1503141112"},{"key":"CIT0057","unstructured":"The Pew Charitable Trusts. Tracking the Pipeline of Antibiotics in Development 2017 [cited January 27, 2017]. Available from: http:\/\/www.pewtrusts.org\/en\/research-and-analysis\/collections\/2016\/12\/tracking-the-pipeline-of-antibiotics-in-development."},{"key":"CIT0058","unstructured":"BIO Industry Analysis. Clinical Development Success Rates 2006-2015. 2016 [09 March 2017]. Available from: https:\/\/www.bio.org\/sites\/default\/files\/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf."},{"key":"CIT0059","unstructured":"Gupta V, Olesky M, Tabak YP, et al. National prevalence of carbapenem-resistant Enterobacteriaceae (CRE) in the ambulatory and acute care settings in the United States in 2015-2016. Poster 352, ID Week 2016, New Orleans, LA, October 26-30, 2016."},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1086\/677157"},{"key":"CIT0061","unstructured":"Report MW. Vital Signs: CRE. MMWR Morbidity and mortality weekly report. 2013;62:157\u2013160."},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00466-1"}],"updated-by":[{"DOI":"10.1080\/14787210.2017.1358541","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000}}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2017.1308251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T17:21:12Z","timestamp":1599412872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2017.1308251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5,4]]}},"alternative-id":["10.1080\/14787210.2017.1308251"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2017.1308251","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}